In recent years, an increasing number of celebrities have been reported using Ozempic, among others, for weight loss, which has overshadowed its intended use for type 2 diabetes management.
The FDA has approved Wegovy and Zepbound for weight management. However, Ozempic and Mounjaro remain categorized strictly for treating type 2 diabetes, raising ethical concerns.
As demand for these drugs in weight loss contexts soars, shortages have emerged that significantly impact diabetics, who are struggling to access the medications essential for managing their health.
NPR highlights the troubling trend of drugmakers promoting weight loss through advertisements targeting the misuse of medications like Ozempic, which were designed for chronic diseases.
Collection
[
|
...
]